Take This Into Account Before Investing in BMY

By Harris Dyer • Thursday, January 19 12:06 • Permanent Link

Bristol-Myers Squibb Company logged a 1.7% change during today's afternoon session, and is now trading at a price of $73.36 per share. The S&P 500 index moved -0.8%. BMY's trading volume is 2,647,629 compared to the stock's average volume of 9,097,288.

Bristol-Myers Squibb Company trades -10.8% away from its average analyst target price of $82.24 per share. The 20 analysts following the stock have set target prices ranging from $60 to $95, and on average have given Bristol-Myers Squibb Company a rating of buy.

If you are considering an investment in BMY, you'll want to know the following:

Bristol-Myers Squibb Company's current price is 539.7% above its Graham number of $11.47, which implies that at its current valuation it does not offer a margin of safety
Bristol-Myers Squibb Company has moved 11.7% over the last year, and the S&P 500 logged a change of -12.4%
Based on its trailing earnings per share of 3.07, Bristol-Myers Squibb Company has a trailing 12 month Price to Earnings (P/E) ratio of 23.9 while the S&P 500 average is 15.97
BMY has a forward P/E ratio of 9.2 based on its forward 12 month price to earnings (EPS) of $7.99 per share
The company has a price to earnings growth (PEG) ratio of 2.48 — a number near or below 1 signifying that Bristol-Myers Squibb Company is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 4.8 compared to its sector average of 4.07
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide.
Based in New York, the company has 32,200 full time employees and a market cap of $155,975,106,560. Bristol-Myers Squibb Company currently returns an annual dividend yield of 3.0%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.